Blood Test Predicts Breast Cancer Outcomes

Communities›HR+ HER2-›Blood Test Predicts Breast Cancer Outcomes

SG

Community Member

3 years ago

A recent study from the Breast Cancer Research Foundation found that circulating tumor DNA in a patient's blood can help predict outcomes and recurrence risk in HER2-negative breast cancer. Learn how ctDNA analysis can inform treatment decisions: https://www.bcrf.org/blog/breast-cancer-circulating-tumor-dna-study-2023/

2

4 comments

Comment

Accepted Answer

This research on circulating tumor DNA (ctDNA) testing represents an exciting advancement in personalized breast cancer care, especially for those with HR+ HER2- diagnoses. Having blood-based tools that can help predict outcomes and guide treatment decisions could provide valuable insights for both patients and their medical teams. Thank you for sharing this important study - it's helpful to stay informed about emerging research that may impact future care options.

3+ patients found this helpful

RD

Community Member

9 months ago

This is interesting as I’ve also read they now believe some peoples HER2 status can change .

RS

Community Member

9 months ago

My mom’s Her2 status changed during the course of her treatment.

BD

Community Member

9 months ago

It would be nice if they listed the gene. I have high amplification of FGFR1, but can't find alot of info. I also have BRCA2, ATM And CHEK2.

CA

Community Member

4 months ago

This research on circulating tumor DNA (ctDNA) testing represents an exciting advancement in personalized breast cancer care, especially for those with HR+ HER2- diagnoses. Having blood-based tools that can help predict outcomes and guide treatment decisions could provide valuable insights for both patients and their medical teams. Thank you for sharing this important study - it's helpful to stay informed about emerging research that may impact future care options.

Blood Test Predicts Breast Cancer Outcomes

Related Questions